BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
Fred P. Lampropoulos, President and CEO of Merit Medical Systems Inc. (NASDAQ:MMSI), a $5.6 billion medical device company that has delivered a ~14% return over the past year, recently sold 10,000 shares of the company’s common stock. The shares were sold on May 30, 2025, at a weighted average price of $95.12 per share, resulting in a total transaction value of approximately $951,200.
Following this sale, Lampropoulos retains direct ownership of 1,056,028 shares. Additionally, shares are held indirectly by his spouse and through a 401(k) plan. The indirect holdings include 7,734 shares by his spouse and 97,892 shares through the 401(k) plan.
The transaction was disclosed in a filing with the Securities and Exchange Commission, which is a routine requirement for company insiders.
In other recent news, Merit Medical Systems, Inc. has reported several key developments. The company recently completed the acquisition of Biolife Delaware L.L.C. for $120 million in cash, which is expected to contribute between $10 million and $11 million in revenue in 2025 and approximately $18 million in annualized revenue by 2026. Canaccord Genuity responded to this acquisition by raising Merit Medical (TASE:BLWV)’s price target to $112, maintaining a Buy rating. Meanwhile, Needham analysts adjusted their price target for the company to $100 from $116, citing tariff impacts on earnings per share, but also reaffirmed a Buy rating due to Merit Medical’s strong operational performance.
Merit Medical’s first-quarter 2025 earnings exceeded consensus estimates, with a notable increase in gross and operating margins year-over-year. The company also announced Health Canada’s approval of its WRAPSODY Cell-Impermeable Endoprosthesis, which is set to begin commercialization in Canada. The WRAPSODY CIE has shown favorable trial results, demonstrating superior performance in maintaining vascular access for hemodialysis patients compared to traditional methods. These strategic moves and product approvals are expected to bolster Merit Medical’s position in the healthcare sector, offering innovative solutions for medical procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.